Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 7, 2013, Pages 1511-1519

  Pedersen, Ann Christina ^a   Sørensen, Patricia Diana ^a   Jacobsen, Erik Hugger ^a   Madsen, Jonna Skov ^a   Brandslund, Ivan ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

breast cancer; cancer antigen 15 3 (CA 15 3); carcinoembryonic antigene (CEA); human epidermal growth factor receptor 2 (HER2); recurrence; tumour marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; EARLY DIAGNOSIS; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84878289615     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0488     Document Type: Article

References (48)

1. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Teat Rev 2000;26:91-102. (Pubitemid 30182241)
2. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem 2006;52:345-51.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312. (Pubitemid 350232263)
4. European group on tumour marker. EGTM guideline for breast cancer. Available from: Http://www.egtm.eu/recommendations. html. Accessed 22 May, 2012.
5. Molina R, Escudero JM, Munoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012;50:2-21.
6. Sørensen PD, Jacobsen EH, Langkjer ST, Bokmand S,østergaard B, Olsen DA, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009;47:1117-23.
7. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010;201:102-10.
8. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995;1241:407-23. (Pubitemid 26021828)
9. Hilkens J, Vos HL, Wesseling J, Peterse J, Storm J, Boer M, et al. The expression levels of episialin in human carcinomas are sufficiently high to potentially interfere with adhesion and protome metastasis. In: Calvo F, Crepin M, Magdelenat H, editors. Breast cancer advances in biology and therapeutics. Rontrouge, France: John Libbey Eurotext, 1996:281-8.
10. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-34. (Pubitemid 19112371)
11. Hammerström S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
12. Clarke C, Hine KR, Dykes PW, Whitehead TP, Whitfield AG. Carcinoembryonic antigen and smoking. J R Coll Physicians Lond 1980;14:227-8. (Pubitemid 11255098)
13. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:53-67.
14. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266: 1716-20. (Pubitemid 21908361)
15. Molina R, Jo J, Filella X, Bruix J, Castells A, Hauge M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18:188-96. (Pubitemid 27204765)
16. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, et al. Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol 1998;19:1-20. (Pubitemid 128707598)
17. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14:130-6.
18. Valenzuela P, Mateos S, Tello E, L ó pez-Bueno MJ, Garrido N, Gaspar MJ. The contribution of the CEA marker to CA 15-3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003;24: 60-2. (Pubitemid 36268189)
19. Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, DaAmico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999;19:4485-9. (Pubitemid 30042811)
20. Molina R, Zan ón G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
21. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, OaHiggins NJ, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 1995;10:35-41.
22. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 2000;20:4751-5.
23. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival byaearlyasalvage treatment of breast cancer patients: A retrospective 6-year study. Br J Cancer 1997;76:1106-11. (Pubitemid 27434671)
24. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007;27:1963-8. (Pubitemid 46954709)
25. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer: A prospective study. Eur J Cancer 2002; 38:1189-93. (Pubitemid 34603478)
26. Safi F, Kohler I, Röttinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-14. (Pubitemid 20116175)
27. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res 2001;7:2357-62. (Pubitemid 32751636)
28. Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, et al. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumour Biol 2001;22:367-73. (Pubitemid 34062948)
29. Jezersek B, Cervek J, Rudolf Z, Novakovi ć S. Clinical evaluation of potential usefulness of CEA, CA 15-3 and MCA in follow-up of breast cancer patients. Cancer Lett 1996;110:137-44. (Pubitemid 27042932)
30. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat 1995;33:83-8.
31. Al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993;19:74-9. (Pubitemid 23095132)
32. Barros AC, Fry W Jr., Nazario AC, Santos MO, Sato MK. Experience with CA 15.3 as a tumor marker in breast cancer. Eur J Surg Oncol 1994;20:130-3. (Pubitemid 24164466)
33. Sölé tormos G, Nielsen D, Schiøler V, Skovsgaard T, Winkel P, Mouridsen HT, et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol 1993;4:861-9. (Pubitemid 24032094)
34. Safi F, Kohler I, Röttinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991;68:574-82.
35. Colomer R, Ruibal A, GenolláJ, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33. (Pubitemid 19120104)
36. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991;200:81-93.
37. Sütterlin M, Bussen S, Trott S, Caffier H. Predictive value of CEA and CA 15-3 in the follow-up of invasive breast cancer. Anticancer Res 1999;19:2567-70. (Pubitemid 29392414)
38. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrai P, Anselmi L, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs. MCA and MCA-CA15.3 vs. CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006;6:269-77.
39. DaAlessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, et al. Serum tissue polypeptide specific antigen (TPS): A complementary tumor maker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat 2001;68:9-19. (Pubitemid 32928266)
40. Baski ć D, Risti ć P, Pavlovi ć S, Arsenijevi ćn. Serum HER2 and CA 15-3 in breast cancer patients. J BUON 2004;9:289-94. (Pubitemid 40360805)
41. Baskić D, Ristić P, Matić S, Bancović D, Popović S, Arsenijevićn. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers 2007;12:657-67. (Pubitemid 350048080)
42. Fehm T, Jäger W, Kr ämer S, Sohn C, Solomayer E, Wallwiener D, et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004;24:1987-92. (Pubitemid 38954622)
43. Pichon MF, Hacene K, Guepratte S, Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastatis in 128 breast cancer patients. Clin Lab 2004;50;163-70. (Pubitemid 38477540)
44. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erb-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329-36. (Pubitemid 30620285)
45. Molina R, Jo J, Zan ón G, Filella X, Farrus B, Mu ñ oz M, et al. Utility of C-erB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 1996;74:1126-31. (Pubitemid 26333918)
46. Molina R, Jo J, Filella X, Zan ón G, Farrus B, Mu ñ oz M, et al. C-erB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999;19:2551-5. (Pubitemid 29392411)
47. Tafe LJ, Tsongalis GJ. The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med 2012;50:23-30.
48. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)